Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Nicola Klein and Bruce Fireman.
Nicola Klein
Connection Strength
12.813
Bruce Fireman
  1. If Influenza Vaccines Wane, Can We Delay Vaccination Without Compromising Coverage? Clin Infect Dis. 2020 04 10; 70(8):1560-1561.
    View in: PubMed
    Score: 0.723
  2. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012 May; 129(5):809-14.
    View in: PubMed
    Score: 0.415
  3. Incidence and Risk of Coronavirus Disease 2019 Hospitalization Among Unvaccinated Children. Influenza Other Respir Viruses. 2024 Oct; 18(10):e70022.
    View in: PubMed
    Score: 0.247
  4. Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants. AJOG Glob Rep. 2024 Nov; 4(4):100395.
    View in: PubMed
    Score: 0.246
  5. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.243
  6. Recombinant Influenza Vaccine in Adults under 65 Years of Age. Reply. N Engl J Med. 2024 Mar 21; 390(12):1156.
    View in: PubMed
    Score: 0.238
  7. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. Ann Intern Med. 2024 Jan 09.
    View in: PubMed
    Score: 0.234
  8. Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age. N Engl J Med. 2023 Dec 14; 389(24):2245-2255.
    View in: PubMed
    Score: 0.233
  9. Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023. J Infect Dis. 2023 Dec 02.
    View in: PubMed
    Score: 0.233
  10. Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records. BMJ. 2023 Nov 08; 383:e076321.
    View in: PubMed
    Score: 0.232
  11. Effectiveness of COVID-19 vaccination during pregnancy by circulating viral variant. AJOG Glob Rep. 2023 Nov; 3(4):100264.
    View in: PubMed
    Score: 0.228
  12. Individual and neighborhood factors associated with being unvaccinated against COVID-19 among pregnant persons. Hum Vaccin Immunother. 2023 08 01; 19(2):2256042.
    View in: PubMed
    Score: 0.227
  13. Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink. Pediatrics. 2023 Jul 01; 152(1).
    View in: PubMed
    Score: 0.226
  14. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.223
  15. Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life. Nat Commun. 2023 Feb 28; 14(1):894.
    View in: PubMed
    Score: 0.221
  16. Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. J Infect Dis. 2023 Jan 23.
    View in: PubMed
    Score: 0.219
  17. Maternal SARS-CoV-2 Vaccination and Infant Protection Against SARS-CoV-2 During the First 6 Months of Life. Res Sq. 2022 Oct 18.
    View in: PubMed
    Score: 0.215
  18. Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States. Ann Intern Med. 2022 12; 175(12):1169-1771.
    View in: PubMed
    Score: 0.215
  19. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022 10 03; 379:e072141.
    View in: PubMed
    Score: 0.215
  20. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022 08 19; 40(35):5153-5159.
    View in: PubMed
    Score: 0.211
  21. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022 04 01; 5(4):e228879.
    View in: PubMed
    Score: 0.207
  22. Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. Vaccine. 2022 Apr 20; 40(18):2568-2573.
    View in: PubMed
    Score: 0.207
  23. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.206
  24. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.206
  25. Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness. Expert Rev Vaccines. 2021 Oct 08; 1-9.
    View in: PubMed
    Score: 0.201
  26. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021 Sep 08.
    View in: PubMed
    Score: 0.199
  27. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021 Sep 03.
    View in: PubMed
    Score: 0.199
  28. Population-based assessment of risks for severe COVID-19 disease outcomes. Influenza Other Respir Viruses. 2021 Aug 25.
    View in: PubMed
    Score: 0.199
  29. Hypotonic-hyporesponsive Episodes After Diphtheria, Tetanus and Acellular Pertussis Vaccination. Pediatr Infect Dis J. 2021 Aug 20.
    View in: PubMed
    Score: 0.199
  30. A Risk Score to Predict Clostridioides difficile Infection. Open Forum Infect Dis. 2021 Mar; 8(3):ofab052.
    View in: PubMed
    Score: 0.191
  31. Individual and Neighborhood Factors Associated With Failure to Vaccinate Against Influenza During Pregnancy. Am J Epidemiol. 2020 11 02; 189(11):1379-1388.
    View in: PubMed
    Score: 0.188
  32. Evaluation of a Vaccine-Communication Tool for Physicians. J Pediatr. 2020 09; 224:72-78.e1.
    View in: PubMed
    Score: 0.183
  33. Depletion-of-susceptibles Bias in Analyses of Intra-season Waning of Influenza Vaccine Effectiveness. Clin Infect Dis. 2020 03 17; 70(7):1484-1486.
    View in: PubMed
    Score: 0.180
  34. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS One. 2020; 15(2):e0229279.
    View in: PubMed
    Score: 0.179
  35. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine. 2019 08 23; 37(36):5422-5427.
    View in: PubMed
    Score: 0.172
  36. Acellular Pertussis Vaccine Effectiveness Over Time. Pediatrics. 2019 07; 144(1).
    View in: PubMed
    Score: 0.171
  37. Intra-season Waning of Influenza Vaccine Effectiveness. Clin Infect Dis. 2018 Sep 10.
    View in: PubMed
    Score: 0.162
  38. Vaccination Patterns in Children After Autism Spectrum Disorder Diagnosis and in Their Younger Siblings. JAMA Pediatr. 2018 May 01; 172(5):469-475.
    View in: PubMed
    Score: 0.158
  39. Birth outcomes following immunization of pregnant women with pandemic H1N1 influenza vaccine 2009-2010. Vaccine. 2018 05 03; 36(19):2733-2739.
    View in: PubMed
    Score: 0.151
  40. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. Vaccine. 2017 06 08; 35(26):3395-3400.
    View in: PubMed
    Score: 0.148
  41. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. Pediatrics. 2017 May; 139(5).
    View in: PubMed
    Score: 0.147
  42. Risk factors and familial clustering for fever 7-10days after the first dose of measles vaccines. Vaccine. 2017 03 14; 35(12):1615-1621.
    View in: PubMed
    Score: 0.146
  43. Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis. 2016 Dec 01; 63(11):1456-1462.
    View in: PubMed
    Score: 0.141
  44. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016 08 05; 34(36):4293-7.
    View in: PubMed
    Score: 0.139
  45. Case-centered Analysis of Optic Neuritis After Vaccines. Clin Infect Dis. 2016 07 01; 63(1):79-81.
    View in: PubMed
    Score: 0.137
  46. Waning Tdap Effectiveness in Adolescents. Pediatrics. 2016 Mar; 137(3):e20153326.
    View in: PubMed
    Score: 0.135
  47. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015 Feb; 135(2):e321-9.
    View in: PubMed
    Score: 0.126
  48. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013 Dec; 167(12):1111-7.
    View in: PubMed
    Score: 0.116
  49. Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ. 2013 Jul 17; 347:f4249.
    View in: PubMed
    Score: 0.113
  50. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013 Jun; 131(6):e1716-22.
    View in: PubMed
    Score: 0.112
  51. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis. 2013 Jul; 57(2):197-204.
    View in: PubMed
    Score: 0.111
  52. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012 Sep 13; 367(11):1012-9.
    View in: PubMed
    Score: 0.107
  53. Evaluation of immunization rates and safety among children with inborn errors of metabolism. Pediatrics. 2011 May; 127(5):e1139-46.
    View in: PubMed
    Score: 0.097
  54. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010 Jul; 126(1):e1-8.
    View in: PubMed
    Score: 0.092
  55. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. 2010 Jan 22; 28(4):1062-8.
    View in: PubMed
    Score: 0.088
  56. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007 Sep; 26(9):771-7.
    View in: PubMed
    Score: 0.075
  57. A role for genetics in the immune response to the varicella vaccine. Pediatr Infect Dis J. 2007 Apr; 26(4):300-5.
    View in: PubMed
    Score: 0.073
  58. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
    View in: PubMed
    Score: 0.062
  59. Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: A retrospective study. Vaccine. 2024 Sep 10; 42(26):126312.
    View in: PubMed
    Score: 0.061
  60. Trends in Gonorrhea and Chlamydia Testing and Infections Across the COVID-19 Pandemic in Adolescents and Young Adults in an Integrated Health System. J Adolesc Health. 2024 Dec; 75(6):952-957.
    View in: PubMed
    Score: 0.061
  61. Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study. JMIR Public Health Surveill. 2024 Jun 25; 10:e53807.
    View in: PubMed
    Score: 0.061
  62. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
    View in: PubMed
    Score: 0.060
  63. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged =18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):180-188.
    View in: PubMed
    Score: 0.059
  64. Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season, VISION Network. Clin Infect Dis. 2023 Nov 16.
    View in: PubMed
    Score: 0.058
  65. Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 States, June 2021-March 2023. Clin Infect Dis. 2023 Aug 26.
    View in: PubMed
    Score: 0.057
  66. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 18; 72(33):886-892.
    View in: PubMed
    Score: 0.057
  67. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. Am J Transplant. 2023 07; 23(7):1062-1076.
    View in: PubMed
    Score: 0.057
  68. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023 May 26; 72(21):579-588.
    View in: PubMed
    Score: 0.056
  69. Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021. Vaccine. 2023 08 23; 41(37):5424-5434.
    View in: PubMed
    Score: 0.056
  70. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.
    View in: PubMed
    Score: 0.055
  71. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.055
  72. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1616-1624.
    View in: PubMed
    Score: 0.055
  73. A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination. Vaccine. 2023 01 16; 41(3):844-854.
    View in: PubMed
    Score: 0.054
  74. Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022. J Infect Dis. 2022 Nov 23.
    View in: PubMed
    Score: 0.054
  75. Prescribing for different antibiotic classes across age groups in the Kaiser Permanente Northern California population in association with influenza incidence, 2010-2018. Epidemiol Infect. 2022 10 26; 150:e180.
    View in: PubMed
    Score: 0.054
  76. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 21; 71(42):1335-1342.
    View in: PubMed
    Score: 0.054
  77. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
    View in: PubMed
    Score: 0.053
  78. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 22; 71(29):931-939.
    View in: PubMed
    Score: 0.053
  79. Safety of COVID-19 Vaccination in US Children Ages 5-11 Years. Pediatrics. 2022 May 18.
    View in: PubMed
    Score: 0.052
  80. Adults hospitalized with breakthrough COVID-19 have lower mortality than matched unvaccinated adults. J Intern Med. 2022 Aug; 292(2):377-384.
    View in: PubMed
    Score: 0.052
  81. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
    View in: PubMed
    Score: 0.052
  82. Antibiotic prescribing across age groups in the Kaiser Permanente Northern California population in association with different diagnoses, and with influenza incidence, 2010-2018. Epidemiol Infect. 2022 02 24; 150:e85.
    View in: PubMed
    Score: 0.051
  83. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(4):139-145.
    View in: PubMed
    Score: 0.051
  84. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
    View in: PubMed
    Score: 0.051
  85. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.050
  86. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.050
  87. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.049
  88. Live Attenuated Influenza Vaccination Before 3 Years of Age and Subsequent Development of Asthma: A 14-year Follow-up Study. Pediatr Infect Dis J. 2018 05; 37(5):383-386.
    View in: PubMed
    Score: 0.040
  89. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. Am J Epidemiol. 2018 01 01; 187(1):161-169.
    View in: PubMed
    Score: 0.039
  90. No association between influenza vaccination during pregnancy and adverse birth outcomes. Vaccine. 2017 05 31; 35(24):3186-3190.
    View in: PubMed
    Score: 0.037
  91. Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder. JAMA Pediatr. 2017 Jan 02; 171(1):e163609.
    View in: PubMed
    Score: 0.036
  92. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. 2012 Dec 17; 31(1):271-7.
    View in: PubMed
    Score: 0.026
  93. Immunization and Bell's palsy in children: a case-centered analysis. Am J Epidemiol. 2012 May 01; 175(9):878-85.
    View in: PubMed
    Score: 0.026
  94. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26; 29(46):8279-84.
    View in: PubMed
    Score: 0.025
  95. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics. 2011 May; 127 Suppl 1:S54-64.
    View in: PubMed
    Score: 0.024

© 2024 Kaiser Permanente